Nonetheless a variety of factors that are associated with more or less favorable outcomes are being identified and aggregating such tumor-intrinsic features and tumor-extrinsic factors is likely to lead to models (or algorithms) that can assist identifying those patients most likely to respond to anti-PD-1 therapy and those likely to need alternative approaches including combination immunotherapies. The gene discussed is PDCD1; the disease is neoplasm.